Integral Health Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Integral Health Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.9M	Hold	40,000	–	–	0.78%	38
2026 Q1	$17.9M	Buy	+40,000	New	+$18.7M	0.85%	29
2021 Q2	–	Sell	-14,000	Closed	-$3.01M	–	90
2021 Q1	$3.01M	Buy	+14,000	New	+$3.08M	0.86%	44

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Integral Health Asset Management's VRTX Position: Q2 2026 in Review

Integral Health Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 40,000 shares worth $19.9M. The position accounts for 0.78% of the portfolio, ranked #38.

Integral Health Asset Management first reported a position in VRTX in Q1 2021 and has held it in 3 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Integral Health Asset Management held 40,000 shares of Vertex Pharmaceuticals worth $19.9M as of Q2 2026.
Integral Health Asset Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.78% of Integral Health Asset Management's portfolio in Q2 2026, its #38 holding.
Integral Health Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 3 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.